FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Socinski

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Liza C Villaruz; Mark A Socinski
The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement.
Mark A Socinski; Lecia Vandam Sequist; Tracey Evans; Scott Gettinger; Thomas A Hensing; Belinda Ireland; Thomas E Stinchcombe
Treatment of Stage IV Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
David R Spigel; Mark A Socinski
Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Socinski (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Liza C Villaruz; Mark A Socinski
The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(10):2629-36.
2013: Mark A Socinski; Lecia Vandam Sequist; Tracey Evans; Scott Gettinger; Thomas A Hensing; Belinda Ireland; Thomas E Stinchcombe
Treatment of Stage IV Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Chest 2013;143(5 Suppl):e341S-68S.
2013: David R Spigel; Mark A Socinski
Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(5):587-98.
2013: Thomas E Stinchcombe; Julia Grigorieva; Carrie B Lee; Dominic T Moore; Amy Peterman; Joanna Roder; Mark A Socinski
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(4):443-51.
2013: Mark A Socinski; H Zhang; S R Dakhil; V Hirsh; J K Hon; C J Langer; I Okamoto; J Orsini; R D Page; M F Renschler
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(2):314-21.
2013: Juneko E Grilley-Olson; Craig F Hart; David Hayes; Michele C Hayward; Kirk D Jones; Kevin O Leslie; Diane M Maia; C Ryan Miller; Dominic T Moore; Keith V Nance; Bahjat F Qaqish; Mark A Socinski; Thomas E Stinchcombe; Leigh B Thorne; William D Travis; Matthew D Wilkerson; Xiaoying Yin; Timothy Craig Allen; Peter M Banks; Mary B Beasley; Alain C Borczuk; Christopher R Cabanski; Philip T Cagle; Rebecca Christensen; Thomas V Colby; Georgean G Deblois; Göran Elmberger; Paolo Graziano; William K Funkhouser
Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets.
Archives of pathology & laboratory medicine 2013;137(1):32-40.
2012: Martin Reck; Egbert F Smit; Ewa Szutowicz-Zielinska; Nick Thatcher; Katherine B Winfree; Susan C Guba; Astra M Liepa; Paul Lorigan; Patrick Peterson; Mark A Socinski
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Lung cancer (Amsterdam, Netherlands) 2012;78(3):276-81.
2012: Mark A Socinski; Thomas E Stinchcombe; W Jeffrey Petty; Garry Schwartz; A. William Blackstock; Roy H Decker; Scott N Gettinger; Amir H Khandani; Scott Lankford; Dominic T Moore; David E Morris
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(32):3953-9.
2012: Daniel S Higginson; Ronald C Chen; Jan Halle; David E Morris; Erica Pham; Julian G Rosenman; Mark A Socinski; Mihaela Stefanescu; Gregg Tracton; Lawrence B Marks
The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma.
International journal of radiation oncology, biology, physics 2012;84(3):e385-92.
2012: Mark A Socinski; Ramaswamy Govindan; David Spigel
Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer.
Clinical advances in hematology & oncology : H&O 2012;10(10 Suppl 18):1-16.
2012: Liza C Villaruz; Gregory J Kubicek; Mark A Socinski
Management of non-small cell lung cancer with oligometastasis.
Current oncology reports 2012;14(4):333-41.
2012: Pasi A Janne; Robert Kratzke; Marzia Capelletti; Jeffrey Crawford; Martin J Edelman; Lin Gu; Mark A Socinski; Thomas E Stinchcombe; Miguel A Villalona-Calero; Everett E Vokes; Xiaofei Wang; Vincent A Miller
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(17):2063-9.
2012: Mark A Socinski; Igor Vynnychenko; Hui Zhang; Paul Bhar; Igor Bondarenko; Vera Hirsh; Jeremy K Hon; Jose L Iglesias; Nina A Karaseva; Anatoly M Makhson; Isamu Okamoto; Markus F Renschler
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(17):2055-62.
2012: Daniel S Higginson; Ronald C Chen; Jan Halle; David E Morris; Julian G Rosenman; Mark A Socinski; Lawrence B Marks
Predicting the need for palliative thoracic radiation after first-line chemotherapy for advanced nonsmall cell lung carcinoma.
Cancer 2012;118(10):2744-51.
2012: Joseph Treat; Matthew J Monberg; Coleman K Obasaju; Guangbin Peng; Giorgio V Scagliotti; Mark A Socinski
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
Lung cancer (Amsterdam, Netherlands) 2012;76(2):222-7.
2012: Matthew D Wilkerson; Xiaoying Yin; Ni Zhao; Philip S Bernard; Christopher R Cabanski; William K Funkhouser; Benjamin Haithcock; Michele C Hayward; C Ryan Miller; Alden M Parsons; Charles M Perou; Scott H Randell; Mark A Socinski; Leigh B Thorne; Nirmal K Veeramachaneni; Vonn Walter; David Hayes
Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.
PloS one 2012;7(5):e36530.
2011: Mark A Socinski
Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
Cancer treatment reviews 2011;37(8):611-7.
2011: Joseph K Salama; Mark A Socinski; Thomas E Stinchcombe; Everett E Vokes; Xiaofei Wang; A. William Blackstock; Jeffrey A Bogart; Jeffrey C Crawford; Lin Gu; Karen Morano
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
International journal of radiation oncology, biology, physics 2011;81(4):e269-74.
2011: Thomas E Stinchcombe; Mark Taylor; Kamal Bakri; Jennifer L Beaumont; Daniel S Bradford; Jeffrey M Crane; Harry D Harper; Thomas A Hensing; Carrie B Lee; Edwin McElroy; Dominic T Moore; Harvey B Niell; Sridhar Pal; Amy Peterman; Garry Schwartz; Mark A Socinski
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(9):1569-77.
2011: Mark A Socinski
ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime time.
Oncology (Williston Park, N.Y.) 2011;25(7):601, 604, 607.
2011: David R Spigel; Peter M Townley; David M Waterhouse; Liang Fang; Ibrahim Adiguzel; Jane E Huang; David A Karlin; Leonardo Faoro; Frank Scappaticci; Mark A Socinski
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(16):2215-22.
2011: Rafat H Ansari; Mark A Socinski; Martin J Edelman; Chandra P Belani; René Gonin; Robert B Catalano; Donna M Marinucci; Robert L Comis; Coleman K Obasaju; Ruqin Chen; Matthew J Monberg; Joseph Treat
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Critical reviews in oncology/hematology 2011;78(2):162-71.
2011: Janine M Davies; Nirav S Dhruva; Christine M Walko; Mark A Socinski; Stephen Bernard; D Neil Hayes; William Y Kim; Anastasia Ivanova; Kimberly Keller; Layla R Hilbun; Michael Chiu; Elizabeth Dees; Thomas E Stinchcombe
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Lung cancer (Amsterdam, Netherlands) 2011;71(2):151-5.
2011: Liza C Villaruz; Mark A Socinski
Personalized therapy for non-small cell lung cancer: which drug for which patient?
Seminars in thoracic and cardiovascular surgery 2011;23(4):281-90.
2011: Thomas E Stinchcombe; Mark A Socinski
Maintenance therapy in advanced non-small cell lung cancer: current status and future implications.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(1):174-82.
2010: Mark A Socinski; Robert N Raju; Thomas Stinchcombe; Darren M Kocs; Linda S Couch; David Barrera; Steven R Rousey; Janak K Choksi; Robert Jotte; Debra A Patt; Phillip O Periman; Howard R Schlossberg; Charles H Weissman; Yunfei Wang; Lina Asmar; Sharon Pritchard; Jane Bromund; Guangbin Peng; Joseph Treat; Coleman K Obasaju
Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(12):1963-9.
2010: Joan H Schiller; Joachim von Pawel; Philipp Schütt; Rafat H Ansari; Michael Thomas; Mansoor Saleh; Robert D McCroskey; Wolfgang Pfeifer; Thomas A Marsland; Goetz H Kloecker; Martin Sebastian; Robert Pirker; Raffael Kurek; Claire Beadman; Mark A Socinski
Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(12):1977-85.
2010: Joseph Treat; Martin J Edelman; Chandra P Belani; Mark A Socinski; Matthew J Monberg; Ruqin Chen; Coleman K Obasaju
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2010;70(3):340-6.
2010: Patrick J Roberts; Thomas E Stinchcombe; Channing J Der; Mark A Socinski
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(31):4769-77.
2010: Matthew D Wilkerson; Xiaoying Yin; Katherine A Hoadley; Yufeng Liu; Michele C Hayward; Christopher R Cabanski; Kenneth Muldrew; Ryan Miller; Scott H Randell; Mark A Socinski; Alden M Parsons; William K Funkhouser; Carrie B Lee; Patrick J Roberts; Leigh B Thorne; Philip S Bernard; Charles M Perou; David Hayes
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(19):4864-75.
2010: Thomas E Stinchcombe; Mark A Socinski
Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy.
Nature reviews. Clinical oncology 2010;7(8):426-8.
2010: Coleman K Obasaju; Rafat H Ansari; Mark A Socinski; Ruqin Chen; Matthew J Monberg; Robert B Catalano; Donna M Marinucci; Darla K Liles; Maria-Jose Ribeiro; Robert L Comis; Joseph Treat
A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(7):993-1000.
2010: Mark A Socinski; Georgiy M Manikhas; Daniil L Stroyakovsky; Anatoly N Makhson; Sergey V Cheporov; Sergei V Orlov; Petr K Yablonsky; Paul Bhar; Jose Iglesias
A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(6):852-61.
2010: Mark A Socinski
The emerging role of biomarkers in advanced non-small-cell lung cancer.
Clinical lung cancer 2010;11(3):149-59.
2010: Thomas E Stinchcombe; Juneko E Grilley-Olson; Mark A Socinski
If histology matters...
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(11):1810-2.
2010: Mark A Socinski; Frank Scappaticci; Meghna Samant; Margaret M Kolb; Mark F. Kozloff
Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(3):354-60.
2010: J A Treat; R Gonin; Mark A Socinski; Martin J Edelman; R B Catalano; D M Marinucci; R Ansari; H H Gillenwater; Jr. Kendrith M. Rowland; R L Comis; C K Obasaju; Chandra Belani
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(3):540-7.
2010: Jean-Yves Douillard; Frances A Shepherd; Vera Hirsh; Tony Shu Kam Mok; Mark A Socinski; Radj Gervais; Mei-Lin Liao; Helge Bischoff; Martin Reck; Mark V Sellers; Claire L Watkins; Georgina Speake; Alison A Armour; Edward S Kim
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):744-52.
2010: Thomas E Stinchcombe; Daniel S Bradford; Thomas A Hensing; Renato V LaRocca; Mansoor Saleh; Tracey Evans; Kamal Bakri; Mark A Socinski
A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer.
Cancer investigation 2010;28(2):208-15.
2010: Martin J Edelman; Chandra P Belani; Mark A Socinski; Rafat H Ansari; Coleman K Obasaju; Ruqin Chen; Matthew J Monberg; Joseph Treat
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(1):110-6.
2009: Silvia Novello; Giorgio V Scagliotti; R Rosell; Mark A Socinski; Julie R Brahmer; J Atkins; C Pallares; R Burgess; L Tye; P Selaru; E Wang; R Chao; R Govindan
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.
British journal of cancer 2009;101(9):1543-8.
2009: Benjamin Haithcock; Thomas E Stinchcombe; Mark A Socinski
Treatment of surgically resectable non-small-cell lung cancer in elderly patients.
Clinical lung cancer 2009;10(6):405-9.
2009: Mark A Socinski
Fibroblastic growth factor pathway.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(11 Suppl 3):S1066-7.
2009: Mark A Socinski; Corey J Langer; Jane E Huang; Margaret M Kolb; Peter Compton; Lisa Wang; Wallace Akerley
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(31):5255-61.
2009: Mark A Socinski; Egbert F Smit; Paul Lorigan; Kartik Konduri; Martin Reck; Aleksandra Szczesna; Johnetta Blakely; Piotr Serwatowski; Nina A Karaseva; tudor ciuleanu; Jacek Jassem; Mircea Dediu; Shengyan Hong; Carla Visseren-Grul; Axel-Rainer Hanauske; Coleman K Obasaju; Susan C Guba; Nick Thatcher
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4787-92.
2009: Mark R Green; Howard West; Mark A Socinski; Joanne Willey; Laura Daniels; Kristine Lemke; George Rafferty; Lou Iovino
Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(8):983-7.
2009: Nirav Dhruva; Mark A Socinski
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):e31-2.
2009: Amir H Khandani; William K Funkhouser; Richard Feins; Mark A Socinski
Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancer.
Annals of nuclear medicine 2009;23(6):595-7.
2009: Mark A Socinski
Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(20):3268-70.
2009: Jyoti D Patel; Philip D Bonomi; Mark A Socinski; Ramaswamy Govindan; Shengyan Hong; Coleman Obasaju; Eduardo J Pennella; Allicia C Girvan; Susan C Guba
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Clinical lung cancer 2009;10(4):252-6.
2009: Rogerio Lilenbaum; Victoria M Villaflor; Corey Langer; Kenneth O'Byrne; Mary O'Brien; Helen J Ross; Mark A Socinski; Fred B Oldham; Larissa Sandilac; jack w singer; Philip Bonomi
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(7):869-74.
2009: Maria Rivera; Frank C Detterbeck; Mark A Socinski; Dominic T Moore; Martin J Edelman; Thierry jahan; Rafat H Ansari; James D Luketich; Guangbin Peng; Matthew Monberg; Coleman K Obasaju; Richard J Gralla
Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
Chest 2009;135(6):1588-95.
2009: Mark A Socinski; M N Saleh; D F Trent; T W Dobbs; L M Zehngebot; MARSHALL LEVINE; R Bordoni; P J Stella
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(6):1068-73.
2009: Thomas E Stinchcombe; Mark A Socinski
Current treatments for advanced stage non-small cell lung cancer.
Proceedings of the American Thoracic Society 2009;6(2):233-41.
2009: Richard J Gralla; Martin J Edelman; Frank C Detterbeck; Thierry jahan; David M Loesch; Steven A Limentani; Ramaswamy Govindan; Guangbin Peng; Matthew J Monberg; Coleman K Obasaju; Mark A Socinski
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009;17(3):307-13.
2009: Thomas E Stinchcombe; Mark A Socinski
Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(2):243-50.
2009: Carrie B Lee; Thomas E Stinchcombe; Dominic T Moore; David E Morris; David Hayes; Jan S Halle; Julian G Rosenman; Maria Rivera; Mark A Socinski
Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(1):74-9.
2008: Edward S Kim; Vera Hirsh; Tony Shu Kam Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Lancet 2008;372(9652):1809-18.
2008: Mark A Socinski; Robert N Raju; Marcus Neubauer; David A Smith; Donald A Richards; Michael Savin; Robert L Ruxer; Craig H Reynolds; Feng Zhan; Jane L Bromund; Ruqin Chen; Coleman K Obasaju
Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(11):1308-16.
2008: Thomas E Stinchcombe; Carrie B Lee; Dominic T Moore; Maria Rivera; Jan S Halle; Steven A Limentani; Julian G Rosenman; Mark A Socinski
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(11):1279-85.
2008: Thomas E Stinchcombe; Mark A Socinski
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
The oncologist 2008;13(9):933-44.
2008: Mary E R O'Brien; Mark A Socinski; Alexander Y Popovich; Igor N Bondarenko; Antoaneta Tomova; Borys T Bilynsky; Yevhen S Hotko; Valentin L Ganul; Ippolit Y Kostinsky; Amy J Eisenfeld; Larissa Sandalic; Fred B Oldham; Bruce Bandstra; Alan B Sandler; jack w singer
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(7):728-34.
2008: Corey J Langer; Kenneth J O'Byrne; Mark A Socinski; Sergei M Mikhailov; Krzysztof Leśniewski-Kmak; Martin Smakal; tudor ciuleanu; Sergey V Orlov; Mircea Dediu; David Heigener; Amy J Eisenfeld; Larissa Sandalic; Fred B Oldham; jack w singer; Helen J Ross
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6):623-30.
2008: Mark A Socinski
The current status and evolving role of sunitinib in non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6 Suppl 2):S119-23.
2008: Thomas J Lynch; George R Blumenschein; Jeffrey A Engelman; Igor Espinoza-Delgado; Ramaswamy Govindan; Jeff Hanke; Nasser H Hanna; John V Heymach; Fred R Hirsch; Pasi A Janne; Rogerio Lilenbaum; Ronald B Natale; Gregory J Riely; Lecia V Sequist; Geoffrey I Shapiro; Alice Shaw; Frances A Shepherd; Mark A Socinski; A Gregory Sorensen; Heather A Wakelee; Aaron Weitzman
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6 Suppl 2):S107-12.
2008: Mark A Socinski; A. William Blackstock; Jeffrey A. Bogart; Xiaofei Wang; Michael Munley; Julian G Rosenman; Lin Gu; Gregory A Masters; Peter Ungaro; Arthur Sleeper; Mark Green; Antonius A Miller; Everett E Vokes
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(15):2457-63.
2008: Thomas E Stinchcombe; Mark A Socinski; Carrie B Lee; David Hayes; Dominic T Moore; Richard M Goldberg; Elizabeth Dees
Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(5):521-6.
2008: Mark A Socinski
Bevacizumab as first-line treatment for advanced non-small cell lung cancer.
Drugs of today (Barcelona, Spain : 1998) 2008;44(4):293-301.
2008: Thomas E Stinchcombe; David E Morris; Carrie B Lee; Dominic T Moore; David Hayes; Jan S Halle; Maria Rivera; Julian G Rosenman; Mark A Socinski
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(3):250-7.
2008: Stephen L Graziano; James E Herndon; Mark A Socinski; Xiaofei Wang; Dorothy Watson; Everett Vokes; Mark R Green
Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(2):158-62.
2008: Thomas E Stinchcombe; Harry D Harper; Thomas A Hensing; Dominic T Moore; Jeffery M Crane; James N Atkins; Ellen M Willard; Frank C Detterbeck; Mark A Socinski
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(2):145-51.
2008: Mark A Socinski; Silvia Novello; Julie R Brahmer; Rafael Rosell; Jose M Sanchez; Chandra P Belani; Ramaswamy Govindan; James N Atkins; Heidi H Gillenwater; Cinta Pallares; Lesley Tye; Paulina Selaru; Richard C Chao; Giorgio V Scagliotti
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):650-6.
2008: Thomas E Stinchcombe; Mark A Socinski
Considerations for second-line therapy of non-small cell lung cancer.
The oncologist 2008;13 Suppl 1():28-36.
2008: Frank C Detterbeck; Mark A Socinski; Richard J Gralla; Martin J Edelman; Thierry jahan; David M Loesch; Steven A Limentani; Ramaswamy Govindan; M B Zaman; Zhishen Ye; Matthew J Monberg; Coleman K Obasaju
Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(1):37-45.
2007: Mark A Socinski; Thomas E Stinchcombe
Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5155-7.
2007: Thomas E Stinchcombe; Mark A Socinski; Christine M Walko; Bert O Neil; Frances A Collichio; Anastasia Ivanova; Hua Mu; Michael J Hawkins; Richard M Goldberg; Celeste Lindley; E Claire Dees
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
Cancer chemotherapy and pharmacology 2007;60(5):759-66.
2007: Mark A Socinski; Jeffrey A. Bogart
Limited-stage small-cell lung cancer: the current status of combined-modality therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(26):4137-45.
2007: Mark A Socinski; Richard Crowell; Thomas A Hensing; Corey J Langer; Rogerio Lilenbaum; Alan B Sandler; David E Morris
Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).
Chest 2007;132(3 Suppl):277S-289S.
2007: Maria Q Baggstrom; Thomas E Stinchcombe; Daniel B Fried; Charles Poole; Thomas A Hensing; Mark A Socinski
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(9):845-53.
2007: Thomas E Stinchcombe; Frank C Detterbeck; Li Lin; Maria Rivera; Mark A Socinski
Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(9):819-26.
2007: Johan Vansteenkiste; Primo Lara; Thierry Le Chevalier; Jean-Luc Breton; Philip Bonomi; Alan B Sandler; Mark A Socinski; Catherine Delbaldo; Brent McHenry; David Lebwohl; Ronald Peck; Martin J Edelman; Mark Edelman
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3448-55.
2007: Mark A Socinski
Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4597-601.
2007: Thomas J Lynch; Philip D Bonomi; Charles Butts; Angela M Davies; Jeffrey A Engelman; Ramaswamy Govindan; Roy S Herbst; John V Heymach; Bruce E Johnson; Renato G Martins; Roman Perez-Soler; Gregory J Riely; Alan B Sandler; Lecia V Sequist; Mark A Socinski; Kwok-Kin Wong; Carol S Hart
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4583-8.
2007: Thomas E Stinchcombe; Mark A Socinski
Bevacizumab in the treatment of non-small-cell lung cancer.
Oncogene 2007;26(25):3691-8.
2007: Carrie B Lee; Mark A Socinski
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Reviews on recent clinical trials 2007;2(2):117-20.
2007: Thomas E Stinchcombe; Ruth Walters; Amir H Khandani; Mark A Socinksi; Mark A Socinski
Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(12):1621-3.
2007: Thomas E Stinchcombe; Mark A Socinski
The role of induction therapy for resectable non-small cell lung cancer.
Drugs 2007;67(3):321-32.
2007: Chandra P Belani; Sherry A Marts; Joan Schiller; Mark A Socinski
Women and lung cancer: epidemiology, tumor biology, and emerging trends in clinical research.
Lung cancer (Amsterdam, Netherlands) 2007;55(1):15-23.
2006: Carrie B Lee; Thomas E Stinchcombe; Julian G Rosenman; Mark A Socinski
Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy.
Clinical lung cancer 2006;8(3):195-202.
2006: David Hayes; Stefano Monti; Giovanni Parmigiani; C Blake Gilks; Katsuhiko Naoki; Arindam Bhattacharjee; Mark A Socinski; Charles M Perou; Matthew Meyerson
Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(31):5079-90.
2006: Thomas E Stinchcombe; Mark A Socinski; Lisa Gangarosa; Amir H Khandani
Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4939-40.
2006: Mark A Socinski; Charles Weissman; Lowell L Hart; J Thaddeus Beck; Janak K Choksi; John P Hanson; Diane Prager; Matthew J Monberg; Zhishen Ye; Coleman K Obasaju
Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4840-7.
2006: Rogerio Lilenbaum; Mark A Socinski; Nasser K Altorki; Lowell L Hart; Roger Keresztes; Subramanian Hariharan; Mark E Morrison; Rana Fayyad; Phillip Bonomi
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4825-32.
2006: Mark A Socinski
Update on nanoparticle albumin-bound paclitaxel.
Clinical advances in hematology & oncology : H&O 2006;4(10):745-6.
2006: Patricia Matheis; Mark A Socinski; Craig N Burkhart; Simon Warren; Nancy E Thomas
Treatment of gefitinib-associated folliculitis.
Journal of the American Academy of Dermatology 2006;55(4):710-3.
2006: Thomas A Hensing; Nasser H Hanna; Heidi H Gillenwater; M Gabriella Camboni; Cecilia Allievi; Mark A Socinski
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer.
Anti-cancer drugs 2006;17(6):697-704.
2006: Thomas E Stinchcombe; Daniel B Fried; David E Morris; Mark A Socinski
Combined modality therapy for stage III non-small cell lung cancer.
The oncologist 2006;11(7):809-23.
2006: Thomas E Stinchcombe; Petra Bůzková; Janak Choksi; Mark Taylor; Kamal Bakri; Heidi H Gillenwater; Maureen Tynan; Andrea Mears; Paul E Jones; Mark A Socinski
A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2006;52(3):305-11.
2006: Kathy S Albain; Chandra P Belani; Philip Bonomi; Kenneth J O'Byrne; Joan H Schiller; Mark A Socinski
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.
Clinical lung cancer 2006;7(6):417-9.
2006: Thomas E Stinchcombe; Carrie B Lee; Mark A Socinski
Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status.
Clinical lung cancer 2006;7 Suppl 4():S111-7.
2006: Thomas E Stinchcombe; David E Morris; Dominic T Moore; John H Bechtel; Jan S Halle; Andrea Mears; Katherine Deschesne; Julian G Rosenman; Mark A Socinski
Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
Lung cancer (Amsterdam, Netherlands) 2006;52(1):67-74.
2006: Carrie B Lee; David E Morris; Daniel B Fried; Mark A Socinski
Current and evolving treatment options for limited stage small cell lung cancer.
Current opinion in oncology 2006;18(2):162-72.
2006: Mark A Socinski; Thomas E Stinchcombe; David Hayes; David E Morris
The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy.
Seminars in oncology 2006;33(1 Suppl 1):S32-8.
2006: Thomas E Stinchcombe; Jaeun Choi; Michael J Schell; Andrea Mears; Paul E Jones; Robert V Nachtsheim; Mark A Socinski
Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status.
Lung cancer (Amsterdam, Netherlands) 2006;51(2):237-43.
2006: A. William Blackstock; James E Herndon; Electra D Paskett; Antonius A Miller; Christopher S Lathan; Harvey B Niell; Mark A Socinski; Everett E Vokes; Mark R Green
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):407-12.
2006: Mark A Socinski; Anastasia Ivanova; Kamal Bakri; J Wall; Maria Q Baggstrom; Thomas A Hensing; Andrea Mears; Maureen Tynan; J Beaumont; Amy Peterman; Harvey B Niell
A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(1):104-9.
2005: Mark A Socinski
Seeking new options for the treatment of small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;50 Suppl 1():S25-6.
2005: Everett E Vokes; Jeffrey Crawford; Jeffrey A. Bogart; Mark A Socinski; Gerald Clamon; Mark R Green
Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13 Pt 2):5045s-5050s.
2005: Chandra P Belani; J S Lee; Mark A Socinski; F Robert; David Waterhouse; K Rowland; R Ansari; Rogerio Lilenbaum; R B Natale
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(7):1069-75.
2005: Celeste Lindley; Susan Goodin; Jeannine McCune; Michael Kane; M Ahinee Amamoo; Stacy S Shord; Trin Pham; Sally Yowell; Kevin Laliberte; Michael J Schell; Stephen A Bernard; Mark A Socinski
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
American journal of clinical oncology 2005;28(3):270-6.
2005: Mark A Socinski
Combined modality trials in unresectable stage III non-small cell lung cancer: the Cancer and Leukemia Group B experience.
Seminars in oncology 2005;32(2 Suppl 3):S114-8.
2005: Mark A Socinski; Julian G Rosenman
Chemotherapeutic issues in the management of unresectable stage III non-small cell lung cancer.
Seminars in oncology 2005;32(2 Suppl 3):S18-24.
2005: Julian G Rosenman; Mark A Socinski
Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung cancer?
Seminars in oncology 2005;32(2 Suppl 3):S13-7.
2005: Mark A Socinski; Thomas E Stinchcombe; David Hayes
The evolving role of pemetrexed (Alimta) in lung cancer.
Seminars in oncology 2005;32(2 Suppl 2):S16-22.
2005: Mark A Socinski
Pemetrexed (Alimta) in small cell lung cancer.
Seminars in oncology 2005;32(2 Suppl 2):S1-4.
2005: Heidi H Gillenwater; Thomas E Stinchcombe; Bahjat F Qaqish; Maureen Tyann; Thomas A Hensing; Mark A Socinski
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;47(3):413-9.
2005: Thomas A Hensing; Michael J Schell; Ji-Hyun Lee; Mark A Socinski
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;47(2):253-9.
2005: Heidi H Gillenwater; Jeannine S McCune; Celeste Lindley; Stephanie R Faucette; Stacy S Shord; Angela Donahue; Mark A Socinski; Clinton F Stewart; William C Zamboni; Mark N Kirstein; Dominic Moore
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Cancer investigation 2005;23(6):511-9.
2005: Keith L Miller; Timothy D Shafman; Mitchell S. Anscher; Su-Min Zhou; Robert W Clough; Jennifer Garst; Jeffrey Crawford; Julian G Rosenman; Mark A Socinski; A. William Blackstock; Gregory S Sibley; Lawrence Marks
Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?
International journal of radiation oncology, biology, physics 2005;61(1):64-9.
2004: Thomas E Stinchcombe; Mark A Socinski
Drug development in patients with advanced non-small cell lung cancer and poor performance status.
Seminars in oncology 2004;31(6 Suppl 11):21-6.
2004: Daniel B Fried; David E Morris; Charles Poole; Julian G Rosenman; Jan S Halle; Frank C Detterbeck; Thomas A Hensing; Mark A Socinski
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4837-45.
2004: Mark A Socinski
Adjuvant therapy of resected non-small-cell lung cancer.
Clinical lung cancer 2004;6(3):162-9.
2004: Frank C Detterbeck; Johan Vansteenkiste; David E Morris; Christophe Dooms; Amir H Khandani; Mark A Socinski
Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer.
Chest 2004;126(5):1656-66.
2004: Mark A Socinski; David E Morris; Jan S Halle; Dominic T Moore; Thomas A Hensing; Steven A Limentani; Robert Fraser; Maureen Tynan; Andrea Mears; Maria Rivera; Frank C Detterbeck; Julian G Rosenman
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(21):4341-50.
2004: Lawrence Marks; Jennifer Garst; Mark A Socinski; Gregory S Sibley; A. William Blackstock; James E Herndon; Sunmin Zhou; Timothy D Shafman; Andrea Tisch; Robert Clough; Xiaoli Yu; Andrew Turrisi; Mitchell S. Anscher; Jeffrey Crawford; Julian G Rosenman
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(21):4329-40.
2004: Shannon K Penland; Mark A Socinski
Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation.
Seminars in radiation oncology 2004;14(4):326-34.
2004: Mark A Socinski; C Zhang; James E Herndon; R O Dillman; Gerald Clamon; Everett E Vokes; Wallace Akerley; Jeffrey Crawford; M C Perry; S L Seagren; Mark R Green
Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(7):1033-41.
2004: Mark A Socinski
Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4210s-4214s.
2004: Thomas J Lynch; Alex A. Adjei; Paul A Bunn; Raymond DuBois; David R Gandara; Giuseppe Giaccone; Ramaswamy Govindan; Roy S Herbst; Bruce E Johnson; Fadlo R Khuri; Roman Perez-Soler; Rafael Rosell; Eric K Rowinsky; Alan B Sandler; Giorgio V Scagliotti; Joan H Schiller; Geoffrey I Shapiro; Mark A Socinski; Carol S Hart
Novel agents in the treatment of lung cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4199s-4204s.
2004: Frank C Detterbeck; Steven Falen; Maria Rivera; Jan S Halle; Mark A Socinski
Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer.
Chest 2004;125(6):2300-8.
2004: Frank C Detterbeck; Steven Falen; Maria Rivera; Jan S Halle; Mark A Socinski
Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses.
Chest 2004;125(6):2294-9.
2004: Mark A Socinski
Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy.
Clinical lung cancer 2004;5(5):274-89.
2003: David Cella; Amy Peterman; Stacie A Hudgens; Kimberly Webster; Mark A Socinski
Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).
Cancer 2003;98(4):822-31.
2003: Thomas A Hensing; Amy Peterman; Michael J Schell; Ji-Hyun Lee; Mark A Socinski
The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
Cancer 2003;98(4):779-88.
2003: Mark A Socinski
The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer.
Respiratory care clinics of North America 2003;9(2):207-36.
2003: Stacy S Shord; Stephanie R Faucette; Heidi H Gillenwater; Scott L Pescatore; Roy L Hawke; Mark A Socinski; Celeste Lindley
Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 2003;51(4):328-36.
2003: Mark A Socinski; Marcus A Neubauer; Jairo Olivares; Steven Ketchel; Maureen Tynan; Martha Moore; Ji-Hyun Lee; Kim Davis; Michael J Schell; David H Garfield
Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;40(1):91-7.
2003: Mark A Socinski; Maria Q Baggstrom; Thomas A Hensing
Duration of therapy in advanced, metastatic non-small-cell lung cancer.
Clinical advances in hematology & oncology : H&O 2003;1(1):33-8.
2003: Mark A Socinski; Maria Rivera; Frank C Detterbeck
Gemcitabine-based combinations as preoperative therapy in resectable non-small-cell lung cancer.
Clinical lung cancer 2003;4 Suppl 2():S50-5.
2003: Bert O Neil; Mark A Socinski
96-hour paclitaxel infusions: at least 93 hours too long.
Cancer investigation 2003;21(4):660-2.
2003: Mark A Socinski; David E Morris; Gregory A Masters; Rogerio Lilenbaum
Chemotherapeutic management of stage IV non-small cell lung cancer.
Chest 2003;123(1 Suppl):226S-243S.
2002: Julian G Rosenman; Jan S Halle; Mark A Socinski; Katharin M Deschesne; Dominic T Moore; Harold Johnson; Robert Fraser; David E Morris
High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
International journal of radiation oncology, biology, physics 2002;54(2):348-56.
2002: Mark A Socinski; Alan B Sandler; Valerie K Israel; Heidi H Gillenwater; Langdon L Miller; Paula K Locker; Alessandro Antonellini; Gary L Elfring; Ronald B Natale
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Cancer 2002;95(7):1520-7.
2002: Mark A Socinski; Michael J Schell; Kamal Bakri; Amy Peterman; Ji-Hyun Lee; Paul Unger; Steven Yates; Stacie A Hudgens; Merrill S Kies
Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Cancer 2002;95(6):1265-73.
2002: Fred J Kudrik; Maria Rivera; Paul L Molina; Susan J Maygarden; Mark A Socinski
Hypersensitivity pneumonitis in advanced non-small-cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and a review of the literature.
Clinical lung cancer 2002;4(1):52-6.
2002: Mark A Socinski; Michael J Schell; Amy Peterman; Kamal Bakri; Steven Yates; Robert Gitten; Paul Unger; Joanna Lee; Ji-Hyun Lee; Maureen Tynan; Martha Moore; Merrill S Kies
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1335-43.
2002: Matthew A Arquette; Todd Wasserman; Ramaswamy Govindan; David Garfield; Neil Senzer; Heidi Gillenwater; Mark A Socinski
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.
Seminars in radiation oncology 2002;12(1 Suppl 1):59-61.
2001: Mark A Socinski; Julian G Rosenman; Jan S Halle; Michael J Schell; Y Lin; S Russo; Maria Rivera; J Clark; Steven A Limentani; Robert Fraser; W Mitchell; Frank C Detterbeck
Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial.
Cancer 2001;92(5):1213-23.
2001: Mark A Socinski; Alan B Sandler; Langdon L Miller; Paula K Locker; CK Hanover; Gary L Elfring; Valerie K Israel; Nicoletta Pirotta; Ronald B Natale
Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial.
Clinical lung cancer 2001;2 Suppl 2():S26-33.
2001: A Donahue; Jeannine S McCune; Stephanie R Faucette; Heidi H Gillenwater; R J Kowalski; Mark A Socinski; Celeste Lindley
Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Cancer chemotherapy and pharmacology 2001;47(5):373-9.
2001: Mark A Socinski; Alan B Sandler; Langdon L Miller; Paula K Locker; CK Hanover; Gary L Elfring; Valerie K Israel; Nicoletta Pirotta; Ronald B Natale
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1078-87.
2001: Mark A Socinski; Lawrence Marks; Jennifer Garst; Gregory S Sibley; A. William Blackstock; Andrew Turrisi; James Herndon; S Zhou; Mitchell S. Anscher; Jeffrey Crawford; Timothy D Shafman; Julian G Rosenman
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
The oncologist 2001;6 Suppl 1():20-4.
2000: Heidi H Gillenwater; Maureen Tynan; S Natoli; Michael J Schell; Mark A Socinski
Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial.
Clinical lung cancer 2000;2(2):133-8.
2000: Mark A Socinski; Julian G Rosenman; Michael J Schell; Jan S Halle; S Russo; Maria Rivera; J Clark; Steven A Limentani; Robert Fraser; W Mitchell; Frank C Detterbeck
Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.
Cancer 2000;89(3):534-42.
2000: R B Natale; Mark A Socinski; Alan B Sandler; V P Israel; L Miller
Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.
Oncology (Williston Park, N.Y.) 2000;14(7 Suppl 5):29-34.
2000: Anneke T Schroen; Frank C Detterbeck; R Crawford; Maria Rivera; Mark A Socinski
Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer.
Chest 2000;118(1):129-37.
2000: M S Reif; Mark A Socinski; Maria Rivera
Evidence-based medicine in the treatment of non-small-cell lung cancer.
Clinics in chest medicine 2000;21(1):107-20, ix.
2000: Thomas A Hensing; Frank C Detterbeck; Mark A Socinski
The role of induction therapy in the management of resectable non-small cell lung cancer.
Cancer control : journal of the Moffitt Cancer Center 2000;7(1):45-55.
1999: Mark A Socinski; C J Langer
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.
Seminars in oncology 1999;26(5 Suppl 16):51-61; discussion 71-2.
1999: Mark A Socinski
The current status of adjuvant chemotherapy for resected non-small cell lung cancer.
Seminars in oncology 1999;26(5 Suppl 15):27-33.
1999: Thomas A Hensing; Mark A Socinski
Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer.
Current opinion in pulmonary medicine 1999;5(4):194-200.
1999: Mark A Socinski
Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.
The oncologist 1999;4(5):408-16.
1999: Mark A Socinski; A Steagall; Heidi H Gillenwater
Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.
Cancer investigation 1999;17(3):181-8.
1998: Mark A Socinski; P N Mudd; K M Radomski; A Steagall; P Lawrence; Stephen A Bernard; SP Letrent; P Gonzalez; Kim L R Brouwer
Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.
Anti-cancer drugs 1998;9(7):611-9.
1998: S O Vargas; KO Leslie; Pamela M Vacek; Mark A Socinski; Donald L Weaver
Estrogen-receptor-related protein p29 in primary nonsmall cell lung carcinoma: pathologic and prognostic correlations.
Cancer 1998;82(8):1495-500.
1997: Mark A Socinski; J A Clark; Jan S Halle; A Steagall; B Kaluzny; Julian G Rosenman
Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.
Seminars in oncology 1997;24(4 Suppl 12):S12-117-S12-122.
1997: Mark A Socinski; Thomas C Shea
High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 12):S12-45-S12-51.
1997: Frank C Detterbeck; Mark A Socinski
IIB or not IIB: the current question in staging non-small cell lung cancer.
Chest 1997;112(1):229-34.
1996: Mark A Socinski; Frank C Detterbeck; Maria Rivera; Thomas M Egan; Jan S Halle; Julian G Rosenman
Chemotherapy helps patients with advanced non-small cell carcinoma of the lung.
North Carolina medical journal 1996;57(5):281-6.
1994: Anthony D Elias; Arthur T Skarin; R Gonin; P Oliynyk; P C Stomper; C O'Hara; Mark A Socinski; T Sheldon; P Maggs; Emil Frei
Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results.
American journal of clinical oncology 1994;17(1):26-36.
1994: C M Karn; Mark A Socinski; J A Fletcher; J M Corson; J E Craighead
Cardiac synovial sarcoma with translocation (X;18) associated with asbestos exposure.
Cancer 1994;73(1):74-8.
1991: M J Robertson; Mark A Socinski; Robert J Soiffer; R W Finberg; C Wilson; Kenneth C Anderson; L Bosserman; D N Sang; I F Salkin; Jerome Ritz
Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia.
Bone marrow transplantation 1991;8(2):143-5.
1989: R Sullivan; J P Fredette; Mark A Socinski; A Elias; Karen Antman; L Schnipper; James D Griffin
Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte-macrophage colony-stimulating factor.
British journal of haematology 1989;71(4):475-9.
1988: Mark A Socinski; M B Garnick; P C Stomper; C Y Fung; J P Richie
Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal disease.
The Journal of urology 1988;140(6):1437-41.
1988: K S Antman; James D Griffin; A Elias; Mark A Socinski; L Ryan; Stephen A Cannistra; D Oette; M Whitley; Emil Frei; L E Schnipper
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
The New England journal of medicine 1988;319(10):593-8.
1988: Mark A Socinski; P C Stomper
Radiologic evaluation of nonseminomatous germ cell tumor of the testis.
Seminars in urology 1988;6(3):203-15.
1988: Mark A Socinski; Stephen A Cannistra; R Sullivan; A Elias; Karen Antman; L Schnipper; James D Griffin
Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo.
Blood 1988;72(2):691-7.
1988: P C Stomper; Mark A Socinski; W D Kaplan; M B Garnick
Failure patterns of nonseminomatous testicular germ cell tumors: radiographic analysis of 51 cases.
Radiology 1988;167(3):641-6.
1988: Mark A Socinski; Stephen A Cannistra; A Elias; K H Antman; L Schnipper; James D Griffin
Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man.
Lancet 1988;1(8596):1194-8.
1988: Mark A Socinski; M B Garnick
Acute pancreatitis associated with chemotherapy for germ cell tumors in two patients.
Annals of internal medicine 1988;108(4):567-8.
1987: P C Stomper; C Y Fung; Mark A Socinski; Maxine Jochelson; M B Garnick; J P Richie
Detection of retroperitoneal metastases in early-stage nonseminomatous testicular cancer: analysis of different CT criteria.
AJR. American journal of roentgenology 1987;149(6):1187-90.
1985: William B. Ershler; A L Moore; Mark A Socinski
Specific antibody synthesis in vitro. III. Correlation of in vivo and in vitro antibody response to influenza immunization in young and old subjects.
Journal of clinical & laboratory immunology 1985;16(2):63-7.
1984: Mark A Socinski; William B. Ershler; G Tosato; R. Michael Blaese
Pure red blood cell aplasia associated with chronic Epstein-Barr virus infection: evidence for T cell-mediated suppression of erythroid colony forming units.
The Journal of laboratory and clinical medicine 1984;104(6):995-1006.
1984: William B. Ershler; A L Moore; Mark A Socinski
Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine.
Journal of clinical immunology 1984;4(6):445-54.
1984: Mark A Socinski; J P Frankel; P L Morrow; E L Krawitt
Painless diarrhea secondary to intestinal ischemia. Diagnosis of atheromatous emboli by jejunal biopsy.
Digestive diseases and sciences 1984;29(7):674-7.
1984: Mark A Socinski; William B. Ershler
T cells and erythroid burst forming units in chronic lymphocytic leukemia.
American journal of hematology 1984;16(2):149-59.
1983: William B. Ershler; Mark A Socinski; C J Greene
Bronchogenic cancer, metastases, and aging.
Journal of the American Geriatrics Society 1983;31(11):673-6.
1983: Mark A Socinski; William B. Ershler; J L Belinson
Coexistent breast and vaginal granulocytic sarcoma.
Gynecologic oncology 1983;16(2):299-304.
1983: Mark A Socinski; William B. Ershler; J P Frankel; R J Albertini; A K Ciongoli; E L Krawitt; S L Burns; K F Mangan
Pure RBC aplasia and myasthenia gravis. Coexistence of two diseases associated with thymoma.
Archives of internal medicine 1983;143(3):543-6.